Key Stats for Insulet Stock
- Pre-market price change for Insulet stock: -7%
- $PODD Share Price as of Mar. 13: $220
- 52-Week High: $355
- $PODD Stock Price Target: $354
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Insulet stock (PODD) was down 7% on Friday after the company announced a voluntary recall of specific lots of its Omnipod 5 Pods.
The issue is straightforward.
- Certain Pods from specific manufacturing lots may have a small tear in the internal tubing that delivers insulin.
- When that happens, insulin leaks inside the Pod instead of reaching the patient.
- That means less insulin gets delivered, which can cause blood sugar to spike.
- In serious cases, it can lead to diabetic ketoacidosis, or DKA, a potentially life-threatening condition.
- Insulet has received 18 reports of serious adverse events tied to this issue, including hospitalizations. No deaths have been reported.
The recall only covers specific lots distributed in the United States.
All other Omnipod 5 Pods and Omnipod products remain safe to use.
The affected Pods represent about 1.5% of annual global Omnipod 5 production, and the company says it does not expect any disruption to shipments or new patient starts.
The FDA has been notified.
See analysts’ growth forecasts and price targets for Insulet stock (It’s free) >>>
What the Market Is Telling Us About Insulet Stock
For a medical device company, recalls hit hard and fast.
Insulet stock was already navigating a tougher stretch after posting strong 2025 results but guiding for slightly slower growth in 2026.
A recall adds another layer of uncertainty at an uncomfortable time.
The good news is that the company moved quickly.
Insulet caught the issue through its own monitoring, has already updated its manufacturing processes, and is continuing to ship product without interruption.
That’s the response investors want to see.
But the market is also asking a harder question.
Insulet has reported 18 serious adverse events associated with this batch. That’s a small number relative to the scale of the business, but it’s the kind of headline that shakes confidence in a product that people with diabetes depend on every single day.
Insulet stock had been performing well heading into this news, backed by record new customer starts, expanding margins, and a clear product roadmap through Omnipod 6 and a fully closed-loop system for type 2 patients.
None of that changes with today’s announcement. But recalls remind investors that medical device companies carry risks that go beyond financial guidance.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Insulet Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
